{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:37:59Z","timestamp":1781591879149,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871239"],"award-info":[{"award-number":["81871239"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771705"],"award-info":[{"award-number":["81771705"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["2015JQ8295"],"award-info":[{"award-number":["2015JQ8295"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An effective vaccine that prevents disease caused by hantaviruses is a global public health priority, but up to now, no vaccine has been approved for worldwide use. Therefore, novel vaccines with high prophylaxis efficacy are urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Herein, we designed and synthesized Hantaan virus (HTNV) linear multi-epitope peptide consisting of HLA-A*02-restricted HTNV cytotoxic T cell (CTL) epitope and pan HLA-DR-binding epitope (PADRE), and evaluated the immunogenicity, as well as effectiveness, of multi-epitope peptides in HLA-A2.1\/K\n                      <jats:sup>b<\/jats:sup>\n                      transgenic mice with interferon (IFN)-\u03b3 enzyme-linked immunospot assay, cytotoxic mediator detection, proliferation assay and HTNV-challenge test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results showed that a much higher frequency of specific IFN-\u03b3-secreting CTLs, high levels of granzyme B production, and a strong proliferation capacity of specific CTLs were observed in splenocytes of mice immunized with multi-epitope peptide than in those of a single CTL epitope. Moreover, pre-immunization of multi-epitope peptide could reduce the levels of HTNV RNA loads in the liver, spleen and kidneys of mice, indicating that specific CTL responses induced by multi-epitope peptide could reduce HTNV RNA loads in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study may provide an important foundation for the development of novel peptide vaccines for HTNV prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01421-y","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T06:03:16Z","timestamp":1602050596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1\/Kb transgenic mice"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-3982","authenticated-orcid":false,"given":"Ying","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boquan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"1421_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrmicro3066","volume":"11","author":"A Vaheri","year":"2013","unstructured":"Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, Mustonen J. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol. 2013;11:539\u201350.","journal-title":"Nat Rev Microbiol"},{"key":"1421_CR2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3390\/v11090788","volume":"11","author":"L Laenen","year":"2019","unstructured":"Laenen L, Vergote V, Calisher CH, Klempa B, Klingstrom J, Kuhn JH, Maes P. Hantaviridae: current classification and future perspectives. Viruses. 2019;11:788.","journal-title":"Viruses"},{"key":"1421_CR3","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/1469-0691.12291","volume":"21S","author":"T Avsic-Zupanc","year":"2019","unstructured":"Avsic-Zupanc T, Saksida A, Korva M. Hantavirus infections. Clin Microbiol Infect. 2019;21S:e6\u201316.","journal-title":"Clin Microbiol Infect"},{"key":"1421_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1128\/JVI.00725-11","volume":"86","author":"XD Lin","year":"2012","unstructured":"Lin XD, Guo WP, Wang W, Zou Y, Hao ZY, Zhou DJ, Dong X, Qu YG, Li MH, Tian HF, et al. Migration of Norway rats resulted in the worldwide distribution of Seoul hantavirus today. J Virol. 2012;86:972\u201381.","journal-title":"J Virol"},{"key":"1421_CR5","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.antiviral.2007.10.012","volume":"78","author":"CB Jonsson","year":"2008","unstructured":"Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008;78:162\u20139.","journal-title":"Antiviral Res"},{"key":"1421_CR6","first-page":"1","volume":"6","author":"H Jiang","year":"2016","unstructured":"Jiang H, Du H, Wang LM, Wang PZ, Bai XF. Hemorrhagic fever with renal syndrome: pathogenesis and clinical picture. Front Cell Infect Microbiol. 2016;6:1.","journal-title":"Front Cell Infect Microbiol"},{"key":"1421_CR7","doi-asserted-by":"publisher","first-page":"e0006554","DOI":"10.1371\/journal.pntd.0006554","volume":"12","author":"J He","year":"2018","unstructured":"He J, Christakos G, Wu J, Cazelles B, Qian Q, Mu D, Wang Y, Yin W, Zhang W. Spatiotemporal variation of the association between climate dynamics and HFRS outbreaks in Eastern China during 2005\u20132016 and its geographic determinants. PLoS Negl Trop Dis. 2018;12:e0006554.","journal-title":"PLoS Negl Trop Dis"},{"key":"1421_CR8","doi-asserted-by":"publisher","first-page":"e25691","DOI":"10.1371\/journal.pone.0025691","volume":"6","author":"Y Balabanova","year":"2011","unstructured":"Balabanova Y, Gilsdorf A, Buda S, Burger R, Eckmanns T, Gartner B, Gross U, Haas W, Hamouda O, Hubner J, et al. Communicable diseases prioritized for surveillance and epidemiological research: results of a standardized prioritization procedure in Germany, 2011. PLoS ONE. 2011;6:e25691.","journal-title":"PLoS ONE"},{"key":"1421_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/erv.12.15","volume":"11","author":"CS Schmaljohn","year":"2012","unstructured":"Schmaljohn CS. Vaccines for hantaviruses: progress and issues. Expert Rev Vaccines. 2012;11:511\u20133.","journal-title":"Expert Rev Vaccines"},{"key":"1421_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/v11070610","volume":"11","author":"RL Brocato","year":"2019","unstructured":"Brocato RL, Hooper JW. Progress on the prevention and treatment of hantavirus disease. Viruses. 2019;11:610.","journal-title":"Viruses"},{"key":"1421_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3201\/eid1608.090470","volume":"16","author":"YZ Zhang","year":"2010","unstructured":"Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals. China Emerg Infect Dis. 2010;16:1195\u2013203.","journal-title":"China Emerg Infect Dis"},{"key":"1421_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.23876\/j.krcp.18.0044","volume":"37","author":"Y Yi","year":"2018","unstructured":"Yi Y, Park H, Jung J. Effectiveness of inactivated hantavirus vaccine on the disease severity of hemorrhagic fever with renal syndrome. Kidney Res Clin Pract. 2018;37:366\u201372.","journal-title":"Kidney Res Clin Pract"},{"key":"1421_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.vaccine.2008.10.051","volume":"27","author":"P Spearman","year":"2009","unstructured":"Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009;27:243\u20139.","journal-title":"Vaccine"},{"key":"1421_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nrurol.2017.77","volume":"14","author":"T Kimura","year":"2017","unstructured":"Kimura T, Egawa S, Uemura H. Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol. 2017;14:501\u201310.","journal-title":"Nat Rev Urol"},{"key":"1421_CR15","first-page":"3406","volume":"6","author":"L Muderspach","year":"2000","unstructured":"Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res. 2000;6:3406\u201316.","journal-title":"Clin Cancer Res"},{"key":"1421_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.addr.2005.11.003","volume":"58","author":"SH van der Burg","year":"2006","unstructured":"van der Burg SH, Bijker MS, Welters MJ, Offringa R, Melief CJ. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv Drug Deliv Rev. 2006;58:916\u201330.","journal-title":"Adv Drug Deliv Rev"},{"key":"1421_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/vaccines7010011","volume":"7","author":"F Perdomo-Celis","year":"2019","unstructured":"Perdomo-Celis F, Salvato MS, Medina-Moreno S, Zapata JC. T-cell response to viral hemorrhagic fevers. Vaccines (Basel). 2019;7:11.","journal-title":"Vaccines (Basel)"},{"key":"1421_CR18","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1128\/JVI.05548-11","volume":"85","author":"T Lindgren","year":"2011","unstructured":"Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren HG, Bjorkstrom NK. Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol. 2011;85:10252\u201360.","journal-title":"J Virol"},{"key":"1421_CR19","doi-asserted-by":"publisher","first-page":"11834","DOI":"10.1128\/JVI.01610-15","volume":"89","author":"B Liu","year":"2015","unstructured":"Liu B, Ma Y, Zhang Y, Zhang C, Yi J, Zhuang R, Yu H, Yang A, Jin B. CD8low CD100- T cells identify a novel CD8 T cell subset associated with viral control during human hantaan virus infection. J Virol. 2015;89:11834\u201344.","journal-title":"J Virol"},{"key":"1421_CR20","first-page":"298","volume":"7","author":"Y Ma","year":"2016","unstructured":"Ma Y, Cheng L, Yuan B, Zhang Y, Zhang C, Tang K, Zhuang R, Chen L, Yang K, Zhang F, Jin B. Structure and function of HLA-A*02-restricted hantaan virus cytotoxic T-cell epitope that mediates effective protective responses in HLA-A2.1\/K(b) transgenic mice. Front Immunol. 2016;7:298.","journal-title":"Front Immunol"},{"key":"1421_CR21","doi-asserted-by":"publisher","first-page":"e2076","DOI":"10.1371\/journal.pntd.0002076","volume":"7","author":"Y Ma","year":"2013","unstructured":"Ma Y, Wang J, Yuan B, Wang M, Zhang Y, Xu Z, Zhang C, Liu B, Yi J, Yang K, et al. HLA-A2 and B35 restricted hantaan virus nucleoprotein CD8+ T-cell epitope-specific immune response correlates with milder disease in hemorrhagic fever with renal syndrome. PLoS Negl Trop Dis. 2013;7:e2076.","journal-title":"PLoS Negl Trop Dis"},{"key":"1421_CR22","doi-asserted-by":"publisher","first-page":"e1004788","DOI":"10.1371\/journal.ppat.1004788","volume":"11","author":"Y Ma","year":"2015","unstructured":"Ma Y, Yuan B, Zhuang R, Zhang Y, Liu B, Zhang C, Yu H, Yi J, Yang A, Jin B. Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humans. PLoS Pathog. 2015;11:e1004788.","journal-title":"PLoS Pathog"},{"key":"1421_CR23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3389\/fimmu.2017.01797","volume":"8","author":"K Tang","year":"2017","unstructured":"Tang K, Cheng L, Zhang C, Zhang Y, Zheng X, Zhuang R, Jin B, Zhang F, Ma Y. Novel identified HLA-A*0201-restricted hantaan virus glycoprotein cytotoxic T-cell epitopes could effectively induce protective responses in HLA-A2.1\/K(b) transgenic mice may associate with the severity of hemorrhagic fever with renal syndrome. Front Immunol. 2017;8:1797.","journal-title":"Front Immunol"},{"key":"1421_CR24","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0264-410X(97)00186-2","volume":"15","author":"MF del Guercio","year":"1997","unstructured":"del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E, Hoffman SL, Jones T, Valmori D, Sakaguchi K, et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine. 1997;15:441\u20138.","journal-title":"Vaccine"},{"key":"1421_CR25","doi-asserted-by":"publisher","first-page":"e114155","DOI":"10.1371\/journal.pone.0114155","volume":"9","author":"VP Kashi","year":"2014","unstructured":"Kashi VP, Jacob RA, Shamanna RA, Menon M, Balasiddaiah A, Varghese RK, Bachu M, Ranga U. The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile. PLoS ONE. 2014;9:e114155.","journal-title":"PLoS ONE"},{"key":"1421_CR26","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/onc.2011.395","volume":"31","author":"Y Chen","year":"2012","unstructured":"Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, Frankel FR, Sun B. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene. 2012;31:2140\u201352.","journal-title":"Oncogene"},{"key":"1421_CR27","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/infdis\/jis107","volume":"205","author":"C La Rosa","year":"2012","unstructured":"La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis. 2012;205:1294\u2013304.","journal-title":"J Infect Dis"},{"key":"1421_CR28","doi-asserted-by":"publisher","first-page":"e115711","DOI":"10.1371\/journal.pone.0115711","volume":"9","author":"L Song","year":"2014","unstructured":"Song L, Yang MC, Knoff J, Wu TC, Hung CF. Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment. PLoS ONE. 2014;9:e115711.","journal-title":"PLoS ONE"},{"key":"1421_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S1074-7613(94)80017-0","volume":"1","author":"J Alexander","year":"1994","unstructured":"Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1:751\u201361.","journal-title":"Immunity"},{"key":"1421_CR30","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1099\/vir.0.016766-0","volume":"91","author":"Y Sun","year":"2010","unstructured":"Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, et al. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol. 2010;91:919\u201330.","journal-title":"J Gen Virol"},{"key":"1421_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12026-012-8330-6","volume":"52","author":"J Zhang","year":"2012","unstructured":"Zhang J, Jia Z, Lin Z, Li J, Fu X, Huang Y, Zhao J, Nie L, Hou W, Yuan F, Wu Y. Computational prediction and experimental assessment of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from neutral endopeptidase. Immunol Res. 2012;52:231\u20139.","journal-title":"Immunol Res"},{"key":"1421_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4049\/jimmunol.174.1.195","volume":"174","author":"H Li","year":"2005","unstructured":"Li H, Zhou M, Han J, Zhu X, Dong T, Gao GF, Tien P. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J Immunol. 2005;174:195\u2013204.","journal-title":"J Immunol"},{"key":"1421_CR33","doi-asserted-by":"publisher","first-page":"e88183","DOI":"10.1371\/journal.pone.0088183","volume":"9","author":"L Cheng","year":"2014","unstructured":"Cheng L, Yu L, Wu X, Li K, Wang F, Zhang L, Ye W, Li P, Zhang F, Xu Z. Induction of specific humoral and cellular immune responses in a mouse model following gene fusion of HSP70C and Hantaan virus Gn and S0.7 in an adenoviral vector. PLoS ONE. 2014;9:e88183.","journal-title":"PLoS ONE"},{"key":"1421_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/cas.12050","volume":"104","author":"A Yamada","year":"2013","unstructured":"Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104:15\u201321.","journal-title":"Cancer Sci"},{"key":"1421_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","volume":"8","author":"CJ Melief","year":"2008","unstructured":"Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008;8:351\u201360.","journal-title":"Nat Rev Cancer"},{"key":"1421_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.humimm.2010.02.012","volume":"71","author":"CM Shen","year":"2010","unstructured":"Shen CM, Zhu BF, Ye SH, Liu ML, Yang G, Liu S, Qin HX, Zhang HD, Lucas R, Li SB. Allelic diversity and haplotype structure of HLA loci in the Chinese Han population living in the Guanzhong region of the Shaanxi province. Hum Immunol. 2010;71:627\u201333.","journal-title":"Hum Immunol"},{"key":"1421_CR37","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1182\/blood-2002-03-0926","volume":"100","author":"C La Rosa","year":"2002","unstructured":"La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, Sharan R, Krishnan R, Crooks M, Markel S, Maas R, Diamond DJ. Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood. 2002;100:3681\u20139.","journal-title":"Blood"},{"key":"1421_CR38","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.164.3.1625","volume":"164","author":"J Alexander","year":"2000","unstructured":"Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol. 2000;164:1625\u201333.","journal-title":"J Immunol"},{"key":"1421_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jtbi.2014.01.018","volume":"349","author":"N Nezafat","year":"2014","unstructured":"Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol. 2014;349:121\u201334.","journal-title":"J Theor Biol"},{"key":"1421_CR40","doi-asserted-by":"publisher","first-page":"5366","DOI":"10.4049\/jimmunol.166.9.5366","volume":"166","author":"MP Velders","year":"2001","unstructured":"Velders MP, Weijzen S, Eiben GL, Elmishad AG, Kloetzel PM, Higgins T, Ciccarelli RB, Evans M, Man S, Smith L, Kast WM. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol. 2001;166:5366\u201373.","journal-title":"J Immunol"},{"key":"1421_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri774","volume":"2","author":"DM Pardoll","year":"2002","unstructured":"Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227\u201338.","journal-title":"Nat Rev Immunol"},{"key":"1421_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0264-410X(98)00250-3","volume":"17","author":"I Tsunoda","year":"1999","unstructured":"Tsunoda I, Sette A, Fujinami RS, Oseroff C, Ruppert J, Dahlberg C, Southwood S, Arrhenius T, Kuang LQ, Kubo RT, et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine. 1999;17:675\u201385.","journal-title":"Vaccine"},{"key":"1421_CR43","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1084\/jem.20031111","volume":"199","author":"R Arens","year":"2004","unstructured":"Arens R, Schepers K, Nolte MA, van Oosterwijk MF, van Lier RA, Schumacher TN, van Oers MH. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med. 2004;199:1595\u2013605.","journal-title":"J Exp Med"},{"key":"1421_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.immunol.23.021704.115825","volume":"24","author":"F Castellino","year":"2006","unstructured":"Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. 2006;24:519\u201340.","journal-title":"Annu Rev Immunol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01421-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01421-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T23:01:08Z","timestamp":1633561268000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01421-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1421"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01421-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-30075\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30075\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-30075\/v2","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was conducted in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Health and Medical Research Council of China. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Fourth Military Medical University with the license number XJYYLL-2014437. All procedures were performed under sodium pentobarbital anesthesia, with the best effort to minimize animal suffering.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}